Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager (TCE) innovation, today announced the presentation of new preclinical data for ENA101, its first-in-class bispecific T ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...
Boehringer Ingelheim today announced a clinical trial collaboration with BioNTech to evaluate a novel immuno--oncology combination in extensive--stage small cell lung cancer (ES-SCLC), one of the most ...
FORT MYERS, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, is now offering Bispecific T-cell ...
TOPEKA, Kan. (WIBW) - A recently-approved treatment could take a “bite” out of certain types of lung cancer by using the body’s own tools to fight back. Sharri Stowers’ fight for life started in 2021.
JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results